The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2019 | Daunorubicin and cytarabine approved for AML treatment within NHS Scotland
Zack Pemberton-Whiteley
• 1 Apr 2019
Daunorubicin and cytarabine were both recently approved by SMC for the treatment of AML within NHS Scotland. Zack Pemberton-Whiteley, Leukaemia Care, Worcester, UK, discusses this at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
